Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical giant with a market capitalization of $648.31 billion, has been making waves in the healthcare sector with its innovative treatments and ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

What caused Eli Lilly's stock to fall this week? During an earnings report, management will generally provide investors with a forecast for the next quarter and potentially the full year.

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...